Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Drax hikes interim dividend despite H1 EBITDA fall

(Sharecast News) - Power company Drax said on Thursday that both revenue and underlying earnings had fallen in the six months ended 30 June Drax said adjusted EBITDA came to £460m in H1, down from £515m at the same time a year earlier, reflecting lower achieved power prices, while group revenue dropped 12% to £2.4bn.

Adjusted earnings per share, however, held steady at 65.6p, and Drax hiked its interim dividend by 11.5% to 11.6p per share.

Operationally, biomass generation remained strong, producing 7.1TWh and contributing 5% of UK electricity and 11% of renewables. Pellet production rose 5%, with EBITDA jumping 14% to £74m. Drax's flexible generation portfolio delivered £81m EBITDA, despite planned outages.

Looking ahead, Drax reaffirmed its FY EBITDA guidance of £899m and maintained its post-2027 target of £600-700m annually.

Drax also said it plans to launch a £450m share buyback extension, supported by an expected £500m working capital inflow in 2027.

CEO Will Gardiner said: "During the first half of the year, we made significant progress towards ensuring we continue to play an important role in UK energy security through this decade and beyond, reaching a heads of terms with the UK Government on a low-carbon dispatchable CfD.

"The energy transition is creating significant value opportunities aligned with the UK's energy needs and we will continue to explore investing in those in a disciplined fashion consistent with our capital allocation policy."

As of 0810 BST, Drax shares were up 4.20% at 706.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.